Table 2 Definitions used in describing the treatment given to the cases in a national cohort of patients with extra-pulmonary tuberculosis
From: Treatment outcome of extra-pulmonary tuberculosis in Finland: a cohort study
Treatment group | Drugs used in intensive phase | Duration of intensive phase [days] | Drugs used in continuation phase | Total duration of treatment [months] |
|---|---|---|---|---|
Standard treatment A | isoniazid + rifampicin + pyrazinamide | At least 54 | isoniazid + rifampicin | At least 5 1/2 |
Standard treatment B | isoniazid + rifampicin + ethambutol or streptomycin | At least 54 | isoniazid + rifampicin | At least 8 |
Standard treatment with short intensive phase C | isoniazid + rifampicin + pyrazinamide or ethambutol or streptomycin | Less than 54 | isoniazid + rifampicin | At least 5 1/2 for A At least 8 for B |
Standard treatment D | >4 tuberculosis drugs, including the drugs in Standard treatment A or B | At least 54 | isoniazid + rifampicin + any other anti-tuberculosis drug(s) | At least 5 1/2 for A At least 8 for B |
Other combination of tuberculosis drugs | Non-standard combinations of tuberculosis drugs, excluding the combinations above | NA2 | Any combination of antituberculosis drugs | NA |
Ineffective treatment | One antituberculosis drug used alone or in combination with a drug with limited antituberculosis activity 1 | NA | NA | NA |